Therapeutic Induction of Endogenous Antibiotics
NCT00800930 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2011-12-08
Summary
Shigellosis is one of the major causes of morbidity and mortality in many developing countries. The continued emergence of antibiotic resistant strains has complicated the treatment of shigellosis and has increased the cost of treatment markedly. Antimicrobial peptides are considered as endogenous antibiotic. A mixture of these antimicrobial peptides (LL-37 and beta-defensin) drenches the mucosal epithelial surfaces forming a barrier for invading microorganisms. Recently, we found that Shigella down-regulates the expression of LL-37 and beta-defensin 1 (HBD-1) in the colon of patients during acute shigellosis thereby facilitating bacterial invasion. Both LL-37 and HBD-1 could inhibit the growth of various microbes e.g. S. dysenteriae type 1, S. flexneri, and S. boydii. Our study indicated that bacterial DNA might be a potential mediator for the down- regulation in vitro. Down-regulation of LL-37 and HBD-1 was also seen in watery diarrhea caused by other pathogens. Thus, bacteria-mediated down-regulation of our front line defenses could be one strategy evolved by the pathogens to subvert this host-defense mechanism. gene encoding LL-37 in cultured epithelial cell lines were up-regulated when treated with butyrate; butyrate decreased the severity of Shigella infections in rabbit model. We could reproduce our findings from human i.e. downregulation of CAP-18 (the rabbit homologue to human LL-37) in colon epithelia after infection with Shigella flexneri. CAP-18 reappeared after treatment of the infected rabbits with sodium butyrate. Thus, the rabbit model demonstrated the proof of principal. In this study, we aim to assess the efficacy of sodium butyrate enema in reduction of clinical symptoms and / severity, reduction of inflammatory responses and induction of endogenous antibiotic activity in the rectum in adult patients with shigellosis.
Conditions
- Shigellosis
Interventions
- BIOLOGICAL
-
Sodium Butyrate
Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
- BIOLOGICAL
-
Saline
Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
Sponsors & Collaborators
-
Swedish International Development Cooperation Agency (SIDA)
collaborator OTHER_GOV - collaborator OTHER
-
International Centre for Diarrhoeal Disease Research, Bangladesh
lead OTHER
Principal Investigators
-
Rubhana Raqib, Ph.D. · International Centre for Diarrhoeal Disease Research, Bangladesh
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-01-31
- Primary Completion
- 2008-12-31
- Completion
- 2009-01-31
Countries
- Bangladesh
Study Locations
More Related Trials
-
Maternal Probiotic Intervention to Improve Gut Health - Trial II - Bangladesh
NCT06817031 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
CMTS0929 for Clostridioides Difficile Infection
NCT06836427 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Identification of Correlates of Protection Against Shigella and Enterotoxigenic Escherichia Coli Infections
NCT01638039 ·Status: UNKNOWN ·Phase: NA
-
Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile
NCT02857582 ·Status: COMPLETED ·Phase: PHASE2
-
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
NCT00304356 ·Status: COMPLETED ·Phase: PHASE3
-
Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection
NCT00485134 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain
NCT02816346 ·Status: COMPLETED ·Phase: PHASE1
-
Use of Bismuth Subsalicylate in Clostridium Difficile Colitis
NCT03592082 ·Status: WITHDRAWN ·Phase: PHASE4
-
Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)
NCT01401023 ·Status: COMPLETED ·Phase: NA
-
Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe
NCT01630096 ·Status: UNKNOWN ·Phase: PHASE4
-
Harnessing the Healthy Gut Microbiota to Cure Patients With Recurrent C. Difficile Infection
NCT01372943 ·Status: TERMINATED ·Phase: NA
-
Freeze-dried, Capsulized FMT for RCDI
NCT02399618 ·Status: UNKNOWN ·Phase: PHASE1
-
Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection
NCT03806803 ·Status: COMPLETED ·Phase: PHASE2
-
OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)
NCT00097422 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study of Fecal Microbiota Transplantation in the Treatment of Antibiotic-associated Diarrhea
NCT05990972 ·Status: COMPLETED ·Phase: NA
-
The Protective Immune Response to Attenuated Enterotoxigenic Escherichia Coli Infection
NCT03596827 ·Status: COMPLETED ·Phase: NA
-
Fecal Microbiota Transplant (FMT) for Pouchitis
NCT02428361 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics
NCT03862079 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD
NCT03824795 ·Status: COMPLETED ·Phase: PHASE2
-
Response of Clostridium Difficile Infection to Metronidazole Therapy
NCT00304369 ·Status: COMPLETED
-
The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia
NCT02127749 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)
NCT02782325 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults
NCT05930197 ·Status: COMPLETED ·Phase: PHASE1
-
Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea
NCT02801656 ·Status: WITHDRAWN ·Phase: PHASE3
-
Metagenomic and Metabolomic Reconstitution of Gut Microbiota After Broad Spectrum Antibiotic Therapy
NCT04171466 ·Status: COMPLETED ·Phase: NA